Published in Cancer Weekly, June 29th, 1998
The first of these trials, a Phase I/II study, is conducted by Ian Judson, M.D., Cancer Research Campaign (CRC) Center for Cancer Therapeutics at the Institute for Cancer Research (ICR) and the Royal Marsden Hospital (RMH) in London, United Kingdom.
The study includes up to 24 patients and assesses leakiness of tumor blood vessels as a biological marker for the angiogenic process in addition to monitoring safety and pharmacokinetic parameters for SU5416. Professor Paul Workman, Ph.D.,...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.